Keyphrases
Cell-free DNA (cfDNA)
64%
Tumor Marker
64%
Circulating nucleosomes
58%
CYFRA 21-1
57%
Cancer Patients
53%
Carbohydrate Antigen 19-9 (CA19-9)
48%
Carbohydrate Antigen 125 (CA125)
46%
High Mobility Group Box 1 (HMGB1)
41%
CA 15-3
40%
Prognostic Value
40%
In Cancer
37%
Chemotherapy
33%
Treatment Monitoring
32%
Carcinoembryonic Antigen
31%
SRAGE
31%
N-terminal Pro-brain Natriuretic Peptide (NT-proBNP)
31%
Serum Biomarkers
30%
Healthy Controls
30%
Non-small Cell Lung Cancer (NSCLC)
30%
Colorectal Cancer
29%
Resectable Pancreatic Cancer
29%
Area under the Curve
27%
Malignant Disease
26%
Lung Cancer
26%
Overall Survival
25%
Therapy Response
25%
Preanalytical Phase
25%
Benign Disease
24%
MicroRNA
23%
Tumor
23%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
22%
Non-small Cell Lung Cancer Patients
21%
Pancreatic Cancer
21%
Breast Cancer
21%
Serum Tumor Markers
20%
Pro-gastrin-releasing Peptide (ProGRP)
20%
Healthy Individuals
19%
Method Comparison
19%
Circulating Tumor DNA (ctDNA)
18%
Serum Samples
18%
Immunoassay
17%
Clinical Performance
17%
Congenital Diaphragmatic Hernia
17%
Neuron-specific Enolase
17%
Cell Death
17%
Differential Diagnosis
16%
Nucleosomal DNA
16%
Apoptosis
16%
Breast Cancer Patients
15%
Cancer Disease
15%
Medicine and Dentistry
Biological Marker
100%
Nucleosome
66%
Tumor Marker
52%
Malignant Neoplasm
47%
Cytokeratin 19 Fragment
44%
Carcinoembryonic Antigen
39%
Diseases
35%
Neoplasm
32%
Pancreas Cancer
29%
Colorectal Carcinoma
25%
Treatment Response
25%
Non Small Cell Lung Cancer
25%
Cell-Free DNA
24%
Immunogenic Cell Death
23%
CA 15-3
22%
microRNA
21%
Prostate Cancer
19%
Tumor Antigen
17%
Lung Cancer
17%
Overall Survival
17%
Carbohydrate Antigen
17%
Percutaneous Aortic Valve Replacement
17%
Congenital Diaphragm Hernia
17%
CA-125
16%
Breast Cancer
16%
Receptor
15%
CA 19-9 Antigen
15%
Amino Terminal Sequence
14%
Prostate Specific Antigen
14%
COVID-19
13%
Cancer
12%
Advanced Glycation End-Product
12%
Liver Cancer
12%
Progastrin Releasing Peptide
12%
Brain Natriuretic Peptide
12%
Congenital Heart Defect
12%
High Mobility Group B1 Protein
11%
Lactate Dehydrogenase
11%
Small Cell Lung Cancer
11%
Programmed Cell Death
11%
Cell Culture
10%
Cell Death
10%
Histone
10%
Circulating Tumor DNA
10%
Advanced Glycation End Product Receptor
10%
Neonate
9%
Lung
9%
Neuron Specific Enolase
9%
Persistent Truncus Arteriosus
9%
Percutaneous Coronary Intervention
9%
